BioNTech revenue and financials

BNTX · NASDAQ · USD

$96.32−1.35%−$1.32

Close · October 6, 2026

In the fiscal year ended December 2025, BioNTech reported revenue of €2.87B (+4.32% year over year). The net loss was €1.14B.

Annual revenue · 2025: €2.87B
  1. €61.6M2017
  2. €127.58M2018
  3. €108.6M2019
  4. €482.3M2020
  5. €18.98B2021
  6. €17.31B2022
  7. €3.82B2023
  8. €2.75B2024
  9. €2.87B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+4.32%
2025 vs 2024
Net margin
-39.6%
2024: -24.2%

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets20,34321,07421,98921,34121,63821,18222,53022,40122,23822,25723,00622,207
Current assets15,29715,53216,14715,83115,92915,62618,80418,48618,28218,27419,52718,749
Cash and equivalents9,7419,9397,67510,09310,27010,1859,7629,62510,3778,97711,66413,496
Short-term investments3,7233,7676,0654,0763,3653,5426,0827,0796,9186,6904,8852,253
Receivables2456129857851,4471,0271,5241,1982871,9252,3402,298
Inventory101104111226231254283303340345358416
Net property, plant and equipment1,2181,3181,2911,2411,2421,2681,1831,1591,1251,031972926
Goodwill373371368358364376381374372369363366
Other intangible assets1,4221,5471,6061,3901,4871,511790874862822782666
Long-term investments1,8492,1522,4542,4762,5052,2471,2131,3321,3431,5871,1761,293
Current liabilities1,9491,7652,1422,2231,8511,5352,5232,5232,4261,6062,0711,807
Accounts payable647469535400504444427763882299354223
Long-term debt10266.629.925.227.331.9———2.32.4—
Total debt316303267245270———————
Total liabilities2,5852,3762,7642,8643,1332,2563,1193,2873,1662,2892,7602,340
Total equity (incl. minority)17,75818,69819,22418,47718,50518,92719,41119,11519,07219,96820,24619,867
Retained earnings16,60917,43017,96218,26718,29618,68219,09818,83918,64019,44819,76319,305